¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lympho"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocytoma
    ¸²ÇÁ±¸Á¾
  • lymphocytopenia
    ¸²ÇÁ±¸°¨¼Ò(Áõ)
  • lymphocytopoiesis
    ¸²ÇÁ±¸Çü¼º
  • lymphocytosis
    ¸²ÇÁ±¸Áõ°¡(Áõ)
  • lymphocytosis stimulating factor
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ
  • lymphocytotoxicity
    ¸²ÇÁ±¸µ¶¼º
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • lymphoduct
    ¸²ÇÁ°ü
  • lymphoepithelioma
    ¸²ÇÁ»óÇÇÁ¾
  • lymphogenesis
    ¸²ÇÁÇü¼º
  • lymphogenous
    1. ¸²ÇÁÇü¼º- 2. ¸²ÇÁ¼º-
  • lymphogenous infection
    ¸²ÇÁ¼º°¨¿°
  • lymphogenous metastasis
    ¸²ÇÁ¼ºÀüÀÌ
  • lymphogranuloma
    ¸²ÇÁÀ°¾ÆÁ¾
  • lymphogranuloma venereum
    ¼ºº´¸²ÇÁÀ°¾ÆÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocytic meningitis
    ¸²ÇÁ±¸¼ö¸·¿°
  • lymphocytoma
    ¸²ÇÁ±¸Á¾
  • lymphocytomatosis
    ¸²ÇÁ±¸Á¾Áõ
  • lymphocytopenia
    ¸²ÇÁ±¸°¨¼ÒÁõ
  • lymphocytopoiesis
    ¸²ÇÁ±¸Çü¼º
  • lymphocytopoietic nodule
    ¸²ÇÁ±¸Çü¼º¼ÒÀý
  • lymphocytosis
    ¸²ÇÁ±¸Áõ°¡Áõ
  • lymphocytosis stimulating factor
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • lymphoduct
    (¢¡lymphatic vessel) ¸²ÇÁ°ü
  • lymphoepithelioid lymphoma
    ¸²ÇÁ»óÇǼ¼Æ÷¸ð¾ç¸²ÇÁÁ¾
  • lymphoepithelioma
    ¸²ÇÁ»óÇÇÁ¾
  • lymphogenesis
    ¸²ÇÁÇü¼º
  • lymphogenous
    ¸²ÇÁÇü¼º-
  • lymphogenous infection
    ¸²ÇÁ°¨¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte activating factor (LAF)
    ¸²ÇÁ±¸ Ȱ¼ºÈ­ÀÎÀÚ
  • lymphocyte analysis
    ¸²ÇÁ±¸ºÐ¼®
  • lymphocyte culture, mixed
    È¥ÇÕ ¸²ÇÁ±¸¹è¾ç
  • lymphocyte defined antigen
    ¸²ÇÁ±¸±ÔÁ¤Ç׿ø.
  • lymphocyte development
    ¸²ÇÁ±¸¹ßÀ°
  • lymphocyte dysfunction
    ¸²ÇÁ±¸±â´ÉÀå¾Ö<--ºÎÀü>
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte interaction
    ¸²ÇÁ±¸»óÈ£ÀÛ¿ë.
  • lymphocyte microcytotoxicity assay
    ¸²ÇÁ±¸¼Ò¼¼Æ÷µ¶¼º°Ë»ç
  • lymphocyte production
    ¸²ÇÁ±¸»ý¼º
  • lymphocyte proliferation
    ¸²ÇÁ±¸Áõ½Ä
  • lymphocyte transformation
    ¸²ÇÁ±¸Àüȯ(¡­Ï¹ ï®üµ).
  • lymphocyte, resident
    »óÁÖ¸²ÇÁ±¸
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • C81.0
    Lymphocytic predominance
    ¸²ÇÁ±¸ ¿ìÀ§Çü
  • I89.0
    Lymphoedema, NEC
    ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¸²ÇÁºÎÁ¾
  • C84.3
    Lymphoepithelioid lymphoma
    ¸²ÇÁ»óÇÇ¾ç ¸²ÇÁÁ¾
  • C91
    Lymphoid leukaemia
    ¸²ÇÁ ¹éÇ÷º´
  • C91.9
    Lymphoid leukaemia, unspecified
    »ó¼¼ºÒ¸íÀÇ ¸²ÇÁ ¹éÇ÷º´
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lymphocytotoxicity
    ¸²ÇÁ±¸ µ¶¼º
    ƯÀÌ ¼¼Æ÷ Ç¥¸é¼º Ç׿øÀ» °¡Áø ¸²ÇÁ±¸°¡ Ç×Ç÷û ¹× º¸Ã¼¿Í ÇÔ²² ¹è¾çÇÏ¿´À» ¶§ ¿ëÇØµÇ´Â °úÁ¤°ú °°ÀÌ, ¸²ÇÁ±¸¸¦ ¿ëÇØÇÏ´Â ¼ºÁú ȤÀº ´É·Â.
  • Lymphocytozoon
    Àӯı¸³» ±â»ýÃæ¼Ó
    ¾Æ¸Þ¹Ù ºñ½ÁÇÑ ¿øÃæÀ¸·Î, Àӯı¸³»¿¡ ±â»ýÇÑ´Ù.
  • lymphoepithalial lesion
    ¸²ÇÁ»óÇǼº º´¼Ò
  • lymphoepithelioma
    ¸²ÇÁ»óÇÇÁ¾
    ºñÀεκΠ¸²ÇÁ¾ç Á¶Á÷ÀÇ »óÇÇ ¼¼Æ÷ ¾ÏÀ¸·Î¼­ µ¿¾ç°èÀÇ ÀþÀº »ç¶÷¿¡°Ô Àß ¹ß»ýÇÑ´Ù.
  • lymphoganglin
    ¸²Æ÷ °»±Û¸°
    ¼Ò Àӯļ±ÀÇ ¾Æ¼¼Åæ ¶Ç´Â ¾ËÄÚ¿Ã ¿¢½º·Î, µ¿¹°¿¡ Á¤¸Æ ÁÖ»çÇÏ¸é °­¾Ð ÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
  • lymphoglandula
    Àӯļ±Á¾, Àӯļ±
  • lymphogranuloma
    ÀÓÆÄ À°¾ÆÁ¾
  • lymphography
    ¸²ÇÁ°ü Á¶¿µ¼ú, Àӯİü Á¶¿µ¹ý
    ¸²ÇÁ°ü¿¡ Á¶¿µÁ¦¸¦ ÁÖÀÔÇÏ¿© ¸²ÇÁ°ü°ú ¸²ÇÁÀýÀ» X¼±À¸·Î º¸´Â ¹æ¹ý.
  • lymphoid
    ¸²ÇÁ¾ç, ¸²ÇÁ¾çÀÇ, ¸²ÇÁ±¸¾çÀÇ
  • lymphoid tissue
    ¸²ÇÁ¼º Á¶Á÷, Àӯľç Á¶Á÷, ¸²ÇÁ Á¶Á÷
  • lymphoididity
    Àӯļº, Àӯļ±¿°
  • lymphokine
    ¸²Æ÷Ä«ÀÎ, ¸²Æ÷Ų
    1. Ç׿ø¿¡ ÀÇÇØ Ȱ¼ºÈ­µÈ ¸²ÇÁ±¸°¡ ¹æÃâÇÏ´Â °¡¿ë¼º ´Ü¹é Àü´Þ ¹°ÁúÀÇ ÃÑĪ. 2. Ç׿ø°ú Á¢ÃËÇÏ¿© °¨ÀÛµÈ Àӯı¸¿¡ ÀÇÇØ ºÐºñµÇ´Â ¹°¿¡ ³ì´Â ´Ü¹éÁú Áß°³ÀÚ¸¦ ºÎ¸£´Â °ÍÀÌ´Ù. ´ë½Ä ¼¼Æ÷¸¦ Ȱ¼ºÈ­½Ã۰í Àӯı¸¸¦ º¯Çü½ÃŰ°í ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • lymphology
    ÀÓÆÄÇÐ
  • lymphoma
    ÀÓÆÄÁ¾, ¸²ÇÁÁ¾
    Hodgkin º´À» Æ÷ÇÔÇÏ¿© ¸²ÇÁ¾ç Á¶Á÷ÀÇ Á¾¾ç¼º º´º¯À» ÃÑĪÇÏ´Â ÀÏ¹Ý ¿ë¾î. ¾ç¼º ¸²ÇÁÁ¾Àº µå¹°¸ç, lym
  • lymphomatoid
    ÀÓÆÄÁ¾ ºñ½ÁÇÑ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte cooperation T-cell enhancement of the B-cell response to thymic-dependent antigens.
(12 Dec 1998)
lymphocyte count A count of the number of lymphocytes in the blood.
(12 Dec 1998)
lymphocyte depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
(12 Dec 1998)
lymphocyte function associated antigen A member of the integrin family that is expressed on all leukocytes and binds to ICAM-1 and ICAM-2 on a variety of cells.
(05 Mar 2000)
lymphocyte function-associated antigen-1 A heterodimer molecule widely expressed on cells of haematopoietic origin. Cd11a antigen comprises the alpha chain and the CD18 antigen (antigens, CD18) the beta chain. Lfa-1 is a major receptor of T-cells, B-cells, and granulocytes. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes. Intracellular adhesion molecule-1 (icam-1) has been defined as a ligand for lfa-1.
(12 Dec 1998)
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
lymphocyte specific protein tyrosine kinase p56(lck) <enzyme> This enzyme is a lymphoid specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the il-2 receptor, and is thought to be involved in the earliest steps of tcr-mediated T-cell activation.
Registry number: EC 2.7.11.-
(12 Dec 1998)
lymphocyte subsets A classification of lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
lymphocyte transformation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte transfusion The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
(12 Dec 1998)
lymphocyte-oriented kinase <enzyme> An ste20-like protein kinase; genbank d89728
Registry number: EC 2.7.10.-
Synonym: lok gene product
(26 Jun 1999)
lymphocytes White blood cells that fight infection and disease.
(12 Dec 1998)
lymphocytes, null A class of lymphocytes characterised by the lack of surface markers specific for either t or b lymphocytes.
(12 Dec 1998)
lymphocytes, tumour-infiltrating Lymphocytes that show specificity for autologous tumour cells. Ex vivo isolation and culturing of til with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 2
  • Lymphocyte Count - »õâ The number of LYMPHOCYTES per unit volume of BLOOD.
    Synonyms : Lymphocyte Number, Lymphocyte Count, Total, Lymphocyte Counts, Lymphocyte Counts, Total, Lymphocyte Numbers, Total Lymphocyte Counts
  • Lymphocyte Culture Test, Mixed - »õâ Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
    Synonyms : Mixed Leukocyte Culture Test, Mixed Leukocyte Reaction, Leukocyte Reaction, Mixed, Leukocyte Reactions, Mixed, Lymphocyte Reaction, Mixed, Lymphocyte Reactions, Mixed, Mixed Leukocyte Reactions, Mixed Lymphocyte Reactions
  • Lymphocyte Depletion - »õâ Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
    Synonyms : Depletion, Lymphocyte
  • Lymphocyte Function-Associated Antigen-1 - »õâ An integrin heterodimer widely expressed on cells of hematopoietic origin. CD11A ANTIGEN comprises the alpha chain and the CD18 antigen (ANTIGENS, CD18) the beta chain. Lymphocyte function-associated antigen-1 is a major receptor of T-CELLS; B-CELLS; and GRANULOCYTES. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by NATURAL KILLER CELLS and granulocytes. Intracellular adhesion molecule-1 has been defined as a ligand for lymphocyte function-associated antigen-1.
    Synonyms : Integrin alphaLbeta2, Antigen-1, Lymphocyte Function-Associated, alphaLbeta2, Integrin
  • Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - »õâ This enzyme is a lymphoid-specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the IL-2 receptor, and is thought to be involved in the earliest steps of TCR-mediated T-cell activation.
    Synonyms : Proto-Oncogene Protein c-lck, Proto-Oncogene Protein lck, Kinase, lck, Protein c-lck, Proto-Oncogene, Protein lck, Proto-Oncogene, Proto Oncogene Protein c lck, Proto Oncogene Protein lck, c-lck, Proto-Oncogene Protein, lck, Proto-Oncogene Protein
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 3 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
lymphocytopenia an abnormally small number of lymphocytes in the circulating blood
Ãâó: wordnet.princeton.edu/perl/webwn
lymphocytic choriomeningitis virus the RNA virus that causes lymphocytic choriomeningitis; infects mice and monkeys and dogs and guinea pigs and human beings
Ãâó: wordnet.princeton.edu/perl/webwn
lymphocytic leukemia leukemia characterized by enlargement of lymphoid tissues and lymphocytic cells in the circulating blood
Ãâó: wordnet.princeton.edu/perl/webwn
lymphocytosis an abnormal increase in the number of lymphocytes in the circulating blood
Ãâó: wordnet.princeton.edu/perl/webwn
lymphogranuloma swelling of a lymph node
Ãâó: wordnet.princeton.edu/perl/webwn
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
lympho infectious disease caused by a species of chlamydia bacterium
lympho an abnormally small number of lymphocytes in the circulating blood
lympho the formation of lymphocytes in the bone marrow and lymph nodes and thymus and spleen
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 2
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á